deep vein thrombosis

New Resource Educates about Therapies for DVTA new resource for patients with deep vein thrombosis aims to educate about interventional therapies.
Pallor and swelling in an athlete’s upper armA 15-year-old female presents to the emergency department of a community hospital with acute onset of duskiness in her left arm.
Impact of aspirin in reducing preterm preeclampsiaA study looks at the efficacy of aspirin in reducing preterm preeclampsia. Plus: The CDC reports on antidepressant use in the United States. Also, a look at whether vaginal estrogen postmenopause increases the risk of heart disease and certain types of cancer.
Is managed care overusing inferior vena cava filters?A new study evaluating Humana claims data reveals interesting findings about IVC filter use in managed care.
Study: Shorter hospital stays with XareltoUS hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.
Xarelto reduces hospital stays: StudyHospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants.
DVT patients taking rivaroxaban had fewer hospital admissions, costs, similar subsequent hospital visits vs. standard of carePatients diagnosed with deep vein thrombosis (DVT) and treated with rivaroxaban (Xarelto) were admitted to the hospital less frequently than those treated with the standard treatment of low-molecular-weight heparin (LMWH) and warfarin, according to real-world data presented at the Hospital Medicine 2015 Congress.
FDA drug approvals - October 2014
FDA drug approvals - October 2014FDA actions in brief, fast-track designations, priority review.
Can warfarin improve psychotic symptoms?A study suggests that warfarin use may lead to a decrease in and even long-term remission of psychotic symptoms in patients with schizophrenia.
Apixaban now approved to reduce risk of blood clots after hip, knee surgeryFDA has approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip- or knee-replacement surgery.